This guy Martin Shekryl is nothing but a phony and a blogger with no relevant experience or knowledge to comment such things.There are several holes in his story here are just a few.
*Revascor is a drug (false)
*patients followed up for 6 months(false patients had actually been followed up for median of 18 months)
*4.4 % of revascor patients died at 6 months( false death from cardiac causes was zero over the period)
* he also mentions his team reviewed quite a few CHF studies and the results were similar however no companies, trials or dates are mentioned.
*he also values MSB entirely on CHF and 50% of that for to cephalon whileconvenently forgetting about the other 9 and counting, multi billion dollar aplictions now underway or nearing human trials.
I could go on but follow the link below to find some interesting information on the author Martin Shekrel and
the lack of knowledge and qualifications this blatant downramper has.
https://sites.google.com/site/vatsire/Searching-for-Martin-Shkreli
seekingalpha comments, page-7
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |